Literature DB >> 15953977

Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States).

S Jane Henley1, Michael J Thun, Cari Connell, Eugenia E Calle.   

Abstract

BACKGROUND: Few prospective studies have examined the health risks associated with use of snuff and chewing tobacco.
METHODS: We studied the association between the use of spit tobacco (snuff or chewing tobacco) and mortality among men enrolled in Cancer Prevention Study I (CPS-I) in 1959 or Cancer Prevention Study II (CPS-II) in 1982. Analyses were based on men who reported exclusive use of snuff or chewing tobacco (7745 in CPS-I, 3327 in CPS-II) or no previous use of any tobacco product (69,662 in CPS-I, 111,482 in CPS-II) at baseline. Twelve-year follow-up of CPS-I, and 18-year follow-up of CPS-II identified 11,871 and 19,588 deaths, respectively. Cox proportional hazards models were used to control for age and other covariates.
RESULTS: Men who currently used snuff or chewing tobacco at baseline had higher death rates from all causes than men who did not in both CPS-I (hazard ratio [HR]=1.17, 95% CI=1.11-1.23) and CPS-II (HR=1.18, 95% CI=1.08-1.29). In CPS-I, current use of spit tobacco was statistically significantly associated with death from coronary heart disease (CHD), stroke, and diseases of the respiratory, digestive, and genitourinary systems, but not with death from cancer. In CPS-II, use of these products was significantly associated with death from CHD, stroke, all cancers combined, lung cancer, and cirrhosis. The associations with cardiovascular and other non-malignant endpoints were attenuated, but not eliminated, by controlling for measured covariates. Former use of spit tobacco was not associated with any endpoint in CPS-II. No clear dose response was observed with either the frequency or duration of usage for any endpoint.
CONCLUSIONS: These two prospective studies provide limited evidence that current use of chewing tobacco or snuff may increase mortality from heart disease and stroke.

Entities:  

Mesh:

Year:  2005        PMID: 15953977     DOI: 10.1007/s10552-004-5519-6

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  79 in total

1.  Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation.

Authors:  Katherine R Schiller; Xianghua Luo; Amanda J Anderson; Joni A Jensen; Sharon S Allen; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2012-01-04       Impact factor: 4.244

Review 2.  Pharmacological interventions for the treatment of smokeless tobacco use.

Authors:  Jon O Ebbert; Karl Fagerstrom
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

3.  A pilot study to assess smokeless tobacco use reduction with varenicline.

Authors:  Jon O Ebbert; Ivana T Croghan; Frederick North; Darrell R Schroeder
Journal:  Nicotine Tob Res       Date:  2010-08-19       Impact factor: 4.244

4.  Prevalence of alternative forms of tobacco use in a population of young adult military recruits.

Authors:  Mark W Vander Weg; Alan L Peterson; Jon O Ebbert; Margaret Debon; Robert C Klesges; C Keith Haddock
Journal:  Addict Behav       Date:  2007-07-13       Impact factor: 3.913

5.  Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.

Authors:  Jennifer N Gray; Alison B Breland; Michael Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2008-09       Impact factor: 4.244

Review 6.  Systematic review of the relation between smokeless tobacco and cancer in Europe and North America.

Authors:  Peter N Lee; Jan Hamling
Journal:  BMC Med       Date:  2009-07-29       Impact factor: 8.775

7.  The impact of product information and trials on demand for smokeless tobacco and cigarettes: evidence from experimental auctions.

Authors:  Matthew C Rousu; Richard J O'Connor; James F Thrasher; Kristie M June; Maansi Bansal-Travers; James Pitcavage
Journal:  Prev Med       Date:  2013-12-07       Impact factor: 4.018

8.  Smokeless and dual tobacco use among males surviving childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  James L Klosky; Ashley M Hum; Nan Zhang; Khatidja S Ali; D Kumar Srivastava; Robert C Klesges; Karen M Emmons; Kirsten K Ness; Marilyn Stovall; Leslie L Robison; Melissa M Hudson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-11       Impact factor: 4.254

9.  Comparative effectiveness of the nicotine lozenge and tobacco-free snuff for smokeless tobacco reduction.

Authors:  Jon O Ebbert; Herbert H Severson; Ivana T Croghan; Brian G Danaher; Darrell R Schroeder
Journal:  Addict Behav       Date:  2013-02-04       Impact factor: 3.913

10.  The Minnesota SimSmoke Tobacco Control Policy Model of Smokeless Tobacco and Cigarette Use.

Authors:  David T Levy; Zhe Yuan; Yameng Li; Ann W St Claire; Barbara A Schillo
Journal:  Am J Prev Med       Date:  2019-10       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.